Bota Bio, with operations in the US and China, have announced a commercial development collaboration to increase sustainability while reducing the costs of API manufacturing.

Under the terms of the agreement, Bota Bio and Spain's Medichem will collaborate on advancing two high-value API programs. Bota Bio will develop novel enzymes to catalyze efficient, environmentally sustainable production methods that minimize the need for expensive reagents and intermediates. Medichem will be responsible for the development, scale-up, manufacturing, and marketing of the APIs from its facilities in Spain and Malta.

"The pharmaceutical industry increasingly demands sustainable ways to manufacture important active ingredients. Enzymes provide an excellent solution, however, they are not yet broadly used given the low activity and in-process stability of unengineered enzymes. We are pleased to secure this innovative collaboration with Bota Bio, as Bota Bio has assembled an industry-leading enzyme-engineering team with a track record of transformative improvements in pharmaceutical manufacturing," said Jose Luis Rodriguez Miranda, chief operations officer, Medichem.